CME/CE Course Description- Physicians and Nurses

Considering EGFR Inhibitors for Treatment of SCCHN

General Information Requirements for Successful Completion: In order to receive credit, participants must view 4 audio-visual presentations and fill out the post-test and evaluation form. There are no costs for participating in this activity and receiving CME/CE credit. Certificates are awarded online after successful completion of the post-test and evaluation.
Media:		Internet
Release Date:		August 21, 2006
Expiration Date:		August 20, 2007
Estimated time to complete activity:		60 minutes
Sponsorship:		This CME/CE activity is jointly sponsored by the University of Michigan Medical School, Amedco, LLC and PVI, PeerView Institute for Medical Education.
Support:		This activity is supported by an educational grant from Bristol-Myers Squibb Company.

Faculty

Course Director and Interviewee
Merrill S. Kies, MD
Professor of Medicine
Director, Clinical Programs
Department of Thoracic/Head and Neck Medical Oncology
University of Texas M. D. Anderson Cancer Center
Houston, Texas

Interviewees
James A. Bonner, MD
Professor and Chairman
Department of Radiation Oncology
University of Alabama at Birmingham
Birmingham, Alabama

Ezra Cohen, MD
Assistant Professor
Department of Medicine
Section of Hematology/Oncology
University of Chicago
Chicago, Illinois

David I. Rosenthal, MD
Associate Professor of Radiation Oncology
Director, Head and Neck Translational Research
University of Texas M. D. Anderson Cancer Center
Houston, Texas

CME Reviewer
Bryan James Schneider, MD
Assistant Professor of Medicine
University of Michigan
Ann Arbor, Michigan

CE Reviewers
Katie Spong, RN, LSW
University of Minnesota Home Health Care
St. Paul, Minnesota

Kristine Kemp, RN
Abbott-Northwestern Hospital
Minneapolis, Minnesota

Alexis Houck, RN, MA
Health Partners
Minneapolis, Minnesota

Faculty Disclosures/Conflict of Interest Policy

The University of Michigan Medical School has a conflict of interest policy that requires course faculty to disclose any real or apparent commercial financial affiliations related to the content of their presentations/materials. It is not assumed that these financial interests or affiliations will have an adverse impact on faculty presentations; they are simply noted here to fully inform participants.

Merrill S. Kies, MD, currently has no financial interests/relationships or affiliations in relation to this activity.

James A. Bonner, MD, has a financial interest/relationship or affiliation in the form of:
Consultant for Bristol-Myers Squibb Company and ImClone Systems Incorporated.

Ezra Cohen, MD, currently has no financial interests/relationships or affiliations in relation to this activity.

David I. Rosenthal, MD, currently has no financial interests/relationships or affiliations in relation to this activity.

CME Reviewer: Bryan James Schneider, MD, has a financial interest/relationship or affiliation in the form of:
Speakers Bureau participant with Eli Lilly and Company and Genentech, Inc.

Disclosure of Unlabeled Use

The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use.

No endorsement of unapproved products or uses is made or implied by coverage of these products or uses in our reports. No responsibility is taken for errors or omissions in reports.

Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings.

Target Audience

This activity has been designed to meet the educational needs of oncologists and oncology nurses.

Program Description

In this activity, experts in the treatment of squamous cell cancer of the head and neck (SCCHN) present current data on the efficacy and toxicity of EGFR inhibition in treating SCCHN.

Educational Objectives

Upon completion of this activity, participants will be able to:

•	Review clinical data on the use of EGFR inhibitors in squamous cell carcinoma of the head and neck (SCCHN) and discuss the clinical implications

•	Describe the impact of EGFR inhibitors on overall toxicity burden when added to radiotherapy or chemoradiotherapy in SCCHN

•	Compare the risks and benefits of adding EGFR inhibitors to radiotherapy in SCCHN versus adding chemotherapy

•	Assess the impact of overall toxicity burden in evaluating treatment options in SCCHN

Accreditation and Credit Designation Statements

Physicians
This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of the University of Michigan Medical School and PVI, PeerView Institute for Medical Education. The University of Michigan Medical School is accredited by the ACCME to provide continuing medical education for physicians.

The University of Michigan Medical School designates this educational activity for a maximum of 1.0 AMA PRA
Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Nurses
This course is co-provided by Amedco, LLC and PVI, PeerView Institute for Medical Education. Amedco, LLC, St. Paul, MN, is an approved provider of nursing continuing education by the Wisconsin Nurses Association Continuing Education Approval Program Committee, an accredited approver by the American Nurses Credentialing Center's Commission on Accreditation.
1.2 contact hour(s).

Click here to fill out the evaluation form and post-test.

Hardware/Software Requirements

PeerView Press requires version 6.x browsers or higher from Microsoft or Netscape. Certain activities may require additional software to view. These activities will be marked as such and will provide links to the required software.
That software may be: Adobe Acrobat®, and Macromedia® Flash.

Privacy Policy

PeerView Press shares your concerns about maintaining the privacy of personal information collected on the Internet. PeerView Press ensures that confidentiality of data relating to individual visitors to a medical/health web site, including their identity, is respected by this web site. The web site owners undertake to honor or exceed the legal requirements of medical/health information privacy that apply in the country and state where the web site and mirror sites are located.

Privacy Policy Changes:
Minor changes to our privacy policy may occur. If privacy policies change in a way that significantly affects the way we handle personal information, we will not use the information we have previously collected without obtaining consent. We will post all privacy policy changes on our web site in a timely manner.

Collection of Personal Information from Site Users:
Visitors to PeerView Press can access and browse the site, without disclosing any personally identifiable information. PeerView Press does track some information provided by your browser, such as the time and date of access, the web site you came from, the type of browser used, and other information that does not personally identify you. Visitors registering for services such as email updates, or completing program evaluation forms are requested to provide personal information, such as name, contact information, and medical specialty. We clearly label which information is required for registration, and which information is optional, on our registration forms. PeerView Press will not collect personally identifiable information without consent and will not share this data with any external partners.
Click here to see the full PeerView Press Privacy Policy

Disclaimer

The participants of this educational activity have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients' conditions and possible contraindications on dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.